KRTL Holding Group Announces KRTL Biotech Inc. Signs MOU with Industria Químico Farmacéutica Sigma Corp. S.R.L. to Pursue Strategic International Merger
KRTL Holding Group (OTC: KRTL) has announced that its subsidiary KRTL Biotech Inc. has signed a Memorandum of Understanding (MOU) with Bolivia's Industria Químico Farmacéutica Sigma Corp for a strategic international merger. The agreement includes shared governance structure and consolidated financial oversight, with Sigma maintaining operational autonomy in Bolivia.
Key terms include Sigma receiving one Special 2021 Series A Preferred Share in KRTL Holding Group and board representation. Financial integration will be managed through SIGMARTL Corp, a U.S.-based entity. The merger aims to integrate Sigma's manufacturing operations and revenue streams into KRTL Biotech, facilitating U.S. market entry for Sigma's pharmaceutical products.
Sigma currently generates annual revenues exceeding $20 million, with facilities operating at 40% capacity. The merged entity projects potential revenue doubling within two years post-integration. The deal is expected to enhance operational efficiency and expand KRTL's presence in international pharmaceutical production.
KRTL Holding Group (OTC: KRTL) ha annunciato che la sua sussidiaria KRTL Biotech Inc. ha firmato un Memorandum of Understanding (MOU) con la Industria Químico Farmacéutica Sigma Corp della Bolivia per una fusione strategica internazionale. L'accordo include una struttura di governance condivisa e un controllo finanziario consolidato, con Sigma che mantiene l'autonomia operativa in Bolivia.
I termini chiave includono che Sigma riceverà un'azione preferenziale speciale della Serie A 2021 in KRTL Holding Group e rappresentanza nel consiglio. L'integrazione finanziaria sarà gestita attraverso SIGMARTL Corp, un'entità con sede negli Stati Uniti. La fusione mira a integrare le operazioni di produzione e i flussi di entrate di Sigma in KRTL Biotech, facilitando l'ingresso nel mercato statunitense per i prodotti farmaceutici di Sigma.
Attualmente, Sigma genera ricavi annuali superiori ai 20 milioni di dollari, con impianti che operano al 40% della capacità. L'entità fusa prevede un raddoppio dei ricavi potenziali entro due anni dopo l'integrazione. L'accordo dovrebbe migliorare l'efficienza operativa ed espandere la presenza di KRTL nella produzione farmaceutica internazionale.
KRTL Holding Group (OTC: KRTL) ha anunciado que su filial KRTL Biotech Inc. ha firmado un Memorando de Entendimiento (MOU) con la Industria Químico Farmacéutica Sigma Corp de Bolivia para una fusión estratégica internacional. El acuerdo incluye una estructura de gobernanza compartida y supervisión financiera consolidada, con Sigma manteniendo la autonomía operativa en Bolivia.
Los términos clave incluyen que Sigma recibirá una acción preferente especial de la Serie A 2021 en KRTL Holding Group y representación en la junta. La integración financiera será gestionada a través de SIGMARTL Corp, una entidad con sede en EE. UU. La fusión tiene como objetivo integrar las operaciones de fabricación y los flujos de ingresos de Sigma en KRTL Biotech, facilitando la entrada al mercado estadounidense para los productos farmacéuticos de Sigma.
Actualmente, Sigma genera ingresos anuales superiores a 20 millones de dólares, con instalaciones que operan al 40% de su capacidad. La entidad fusionada proyecta un posible duplicado de ingresos dentro de dos años después de la integración. Se espera que el acuerdo mejore la eficiencia operativa y expanda la presencia de KRTL en la producción farmacéutica internacional.
KRTL 홀딩 그룹 (OTC: KRTL)은 자회사 KRTL 바이오텍 Inc.가 볼리비아의 산업 화학 제약 Sigma Corp와 전략적 국제 합병을 위한 양해각서(MOU)를 체결했다고 발표했습니다. 이 계약에는 공유 거버넌스 구조와 통합 재무 감독이 포함되며, Sigma는 볼리비아에서 운영 자율성을 유지합니다.
주요 조건으로는 Sigma가 KRTL 홀딩 그룹에서 2021년 특별 A 시리즈 우선주 1주를 받고 이사회에서의 대표 권한을 포함합니다. 재무 통합은 미국에 본사를 둔 SIGMARTL Corp를 통해 관리됩니다. 이번 합병은 Sigma의 제조 운영 및 수익원을 KRTL 바이오텍에 통합하여 Sigma의 제약 제품이 미국 시장에 진입할 수 있도록 하는 것을 목표로 합니다.
Sigma는 현재 연간 2천만 달러 이상의 수익을 창출하고 있으며, 시설은 40%의 용량으로 운영되고 있습니다. 합병된 법인은 통합 후 2년 이내에 수익이 두 배로 증가할 것으로 예상하고 있습니다. 이번 거래는 운영 효율성을 높이고 KRTL의 국제 제약 생산에서의 입지를 확장할 것으로 기대됩니다.
KRTL Holding Group (OTC: KRTL) a annoncé que sa filiale KRTL Biotech Inc. a signé un Mémorandum d'Entente (MOU) avec la Industria Químico Farmacéutica Sigma Corp de Bolivie pour une fusion stratégique internationale. L'accord comprend une structure de gouvernance partagée et une supervision financière consolidée, Sigma conservant son autonomie opérationnelle en Bolivie.
Les conditions clés incluent que Sigma recevra une action préférentielle spéciale de la série A 2021 dans KRTL Holding Group et une représentation au conseil d'administration. L'intégration financière sera gérée par SIGMARTL Corp, une entité basée aux États-Unis. La fusion vise à intégrer les opérations de fabrication et les flux de revenus de Sigma dans KRTL Biotech, facilitant ainsi l'entrée sur le marché américain pour les produits pharmaceutiques de Sigma.
Actuellement, Sigma génère des revenus annuels dépassant 20 millions de dollars, avec des installations fonctionnant à 40 % de leur capacité. L'entité fusionnée prévoit un doublement potentiel des revenus dans les deux ans suivant l'intégration. L'accord devrait améliorer l'efficacité opérationnelle et élargir la présence de KRTL dans la production pharmaceutique internationale.
KRTL Holding Group (OTC: KRTL) hat angekündigt, dass ihre Tochtergesellschaft KRTL Biotech Inc. ein Memorandum of Understanding (MOU) mit Boliviens Industria Químico Farmacéutica Sigma Corp für eine strategische internationale Fusion unterzeichnet hat. Die Vereinbarung umfasst eine gemeinsame Governance-Struktur und konsolidierte Finanzaufsicht, wobei Sigma die operative Autonomie in Bolivien behält.
Zu den wichtigsten Bedingungen gehört, dass Sigma eine spezielle Vorzugsaktie der Serie A 2021 in der KRTL Holding Group erhält und im Vorstand vertreten ist. Die finanzielle Integration wird über die in den USA ansässige SIGMARTL Corp verwaltet. Ziel der Fusion ist es, die Produktionsabläufe und Einnahmequellen von Sigma in KRTL Biotech zu integrieren und den Markteintritt von Sigmas pharmazeutischen Produkten in den USA zu erleichtern.
Derzeit erzielt Sigma jährliche Einnahmen von über 20 Millionen Dollar, wobei die Anlagen mit 40 % ihrer Kapazität betrieben werden. Das fusionierte Unternehmen rechnet damit, dass sich die Einnahmen innerhalb von zwei Jahren nach der Integration verdoppeln könnten. Der Deal wird voraussichtlich die Betriebseffizienz verbessern und die Präsenz von KRTL in der internationalen pharmazeutischen Produktion erweitern.
- Potential revenue doubling within two years post-merger
- Current annual revenue stream of $20+ million from Sigma
- Opportunity to increase facility utilization from 40% to full capacity
- Access to US pharmaceutical market through KRTL's regulatory framework
- Enhanced international pharmaceutical production capabilities
- Current underutilization of Sigma's production facilities at 40% capacity
- Complex international merger requiring extensive regulatory approvals
- Potential shareholder dilution through equity issuance to Sigma
Lakewood, CO, March 24, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL), a diversified holding company operating through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp., is pleased to announce that its wholly owned subsidiary, KRTL Biotech Inc., has signed a Memorandum of Understanding (MOU) with Industria Químico Farmacéutica Sigma Corp. S.R.L. ("Sigma") of Bolivia. This MOU establishes the framework for a strategic international merger between the two pharmaceutical entities.
Under the terms of the MOU, KRTL Biotech and Sigma have agreed on key merger provisions, including a shared governance structure, consolidated financial oversight, and aligned Quality Management Systems (QMS). Sigma will maintain full operational autonomy in Bolivia, while the partnership focuses on cross-border compliance, coordinated financial operations, and integrated strategic governance.
“This MOU marks a pivotal milestone for KRTL Biotech and a transformative step in our international expansion,” stated Cesar Herrera, CEO of KRTL Holding Group Inc. “By joining forces with Sigma, we are strengthening our global regulatory capabilities and expanding pharmaceutical production capacity across U.S. and South American markets.”
As part of the agreement, Sigma will receive equity in KRTL Holding Group Inc., including one (1) Special 2021 Series A Preferred Share and representation on KRTL Holding's Board of Directors. In addition, key Sigma executives will receive individual common stock allocations to align long-term incentives. Financial integration will be managed through SIGMARTL Corp, a U.S.-based financial management entity designed to track global revenue, ensure compliance, and oversee profit-sharing mechanisms.
The legal structuring and regulatory due diligence of the merger is being managed by a specialized law firm in South America, with experience in international mergers and pharmaceutical regulations. The final Business Merger Agreement, currently under development, will formalize the merger upon securing all necessary legal and financial conditions.
The MOU outlines a strategic plan to consolidate Sigma’s manufacturing operations and revenue streams into KRTL Biotech. This integration is intended to facilitate the import and commercialization of Sigma’s pharmaceutical products in the United States under KRTL’s regulatory and distribution framework. The parties believe that the merger will significantly enhance operational efficiency, enabling Sigma’s production facilities—currently running at approximately
This initiative builds upon KRTL Biotech’s ongoing strategy to establish itself as a central player in international pharmaceutical production, API oversight, and regulatory compliance. The combined operations will enhance production capacity, open new markets, and foster innovation in therapeutic development.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
For more information, please visit:
Forward-Looking Statements
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.
KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.
www.krtlholding.com info@krtlholding.com www.krtlbiotech.com info@krtlbiotech.com www.krtl-icc.com info@krtl-icc.com
FAQ
What are the financial terms of the KRTL-Sigma merger agreement?
How much revenue does Sigma currently generate and what are KRTL's growth projections?
What is the current capacity utilization of Sigma's facilities and how will it change under KRTL?
How will the KRTL-Sigma merger affect pharmaceutical distribution in the US market?
What operational changes will occur at Sigma following the KRTL merger?
